{"product_id":"ildong-marketing-mix","title":"Ildong Pharmaceuticals Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong Pharmaceutical: 4Ps Marketing Mix Overview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis 4Ps snapshot examines product choices, pricing, distribution, and promotion for Ildong Pharmaceutical across prescription and OTC markets. The preview outlines core strategies-portfolio focus, value-based pricing, targeted channels, and evidence-led communications-while the full, editable 4Ps report gives detailed tactics, channel economics, and promotion plans you can use for coursework or practical marketing projects. Access the complete analysis to save research time and apply a clear framework to your work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Prescription Drug Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals maintains a diverse prescription portfolio focused on chronic diseases-hypertension, dyslipidemia, and diabetes-driving stable demand among South Korea's aging population (20% aged 65+ in 2024). The firm pairs high-quality generics with licensed original drugs, capturing an estimated 7-9% share in outpatient cardiometabolic prescriptions as of 2024. By end-2025 the prescription division remains the primary revenue driver, with gastroenterology and cardiovascular treatments accounting for roughly 45% of prescription sales (~KRW 220 billion in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAronamin Legacy OTC Brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAronamin Legacy is Ildong Pharmaceuticals' flagship OTC vitamin line in Korea, with over 60 years of brand trust and estimated retail sales of ~KRW 120 billion in 2024, driving ~25% of Ildong's consumer health revenue.\u003c\/p\u003e\n\u003cp\u003eIldong expanded Aronamin into Aronamin Gold, C-Plus, and Eyes to target seniors, immunity-seekers, and digital-age eye strain, each claiming tailored nutrient blends and priced 10-25% above core SKU.\u003c\/p\u003e\n\u003cp\u003ePackaging and marketing stress fatigue recovery and daily supplementation for busy professionals, using workplace-focused TV and digital ads that lifted category share by ~3 percentage points in 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Probiotics and Biovita\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals leverages 60+ years of fermentation expertise to revitalize Biovita and expand probiotics under L'il Bita and MyNi, driving a 12% consumer-health sales lift in 2024 (Ildong FY2024 report).\u003c\/p\u003e\n\u003cp\u003eProducts use quadruple-coating tech to boost survival rates above 80% through the stomach, improving efficacy versus standard single-coat rivals (bench tests, 2023).\u003c\/p\u003e\n\u003cp\u003eGut health is a core strategy, targeting infants to seniors; probiotics now represent ~18% of Ildong's OTC portfolio and aim for 25% revenue share by 2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative R\u0026amp;D Pipeline Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIldong shifted toward research-driven biotech by late 2025, targeting first-in-class metabolic and oncology drugs and cutting generics exposure by ~30% of revenue mix since 2022.\u003c\/p\u003e\n\u003cp\u003eIt channels heavy R\u0026amp;D funding into UnoVia, raising subsidiary spend to KRW 120 billion in 2024 and aiming for GLP-1 candidates entering Phase II in 2025.\u003c\/p\u003e\n\u003cp\u003eThe strategy repositions products toward proprietary IP to lift gross margins (target +6-8 ppt) and long-term NPV through high-value assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRevenue mix: generics down ~30% since 2022\u003c\/li\u003e\n\u003cli\u003eUnoVia R\u0026amp;D: KRW 120 billion (2024)\u003c\/li\u003e\n\u003cli\u003eGLP-1: Phase II entry target 2025\u003c\/li\u003e\n\u003cli\u003eTarget margin lift: +6-8 percentage points\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Health and Cosmeceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIldong Pharmaceuticals expanded into beauty and wellness with functional cosmetics and health foods, reporting a 2024 segment revenue of KRW 42 billion (≈USD 31.5M), up 18% year-over-year.\u003c\/p\u003e\n\u003cp\u003eFirst Lab uses pharmaceutical-grade actives and probiotics to position between medical efficacy and daily convenience, targeting health-conscious urban consumers and driving a 12% SKU repeat purchase rate.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue KRW 42B\u003c\/li\u003e\n\u003cli\u003eYoY growth 18%\u003c\/li\u003e\n\u003cli\u003eFirst Lab repeat rate 12%\u003c\/li\u003e\n\u003cli\u003eTarget: urban, health-focused consumers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong pivots to proprietary biotech, GLP‑1 Phase II (2025) to boost margins +6-8ppt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong's product mix centers on cardiometabolic prescription drugs (45% of Rx sales; ~KRW 220B in 2024), Aronamin OTC vitamins (~KRW 120B retail 2024), probiotics (18% of OTC; target 25% by 2026), UnoVia R\u0026amp;D KRW 120B (2024) shifting toward proprietary biotech and GLP‑1 Phase II target 2025 to lift gross margins +6-8 ppt.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/Target\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRx cardiometabolic sales\u003c\/td\u003e\n\u003ctd\u003eKRW 220B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAronamin retail\u003c\/td\u003e\n\u003ctd\u003eKRW 120B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProbiotics share OTC\u003c\/td\u003e\n\u003ctd\u003e18% (2024) → 25% (2026 target)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnoVia R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eKRW 120B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLP‑1\u003c\/td\u003e\n\u003ctd\u003ePhase II target 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Ildong Pharmaceuticals' Product, Price, Place, and Promotion strategies, ideal for managers and consultants needing a clear breakdown of its market positioning grounded in real brand practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Ildong Pharmaceuticals' 4P insights into a concise, leadership-ready snapshot that highlights product positioning, pricing strategy, promotional tactics, and distribution channels to quickly align teams and inform strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Pharmacy Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals uses a nationwide distribution network reaching over 12,000 independent pharmacies across South Korea, ensuring fast shelf availability for OTC brands like Aronamin and supporting same-day restock in major metro areas.\u003c\/p\u003e\n\u003cp\u003ePharmacists account for a primary point-of-sale influence: Ildong runs regular training and co-promotion programs covering roughly 8,000 pharmacists annually, boosting OTC conversion rates by an estimated 15% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Online Ildong Mall\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpildong pharmaceuticals has expanded direct-to-consumer reach via its proprietary e-commerce platform ildong mall launched nationwide in and growing gmv to krw billion by bypassing traditional retailers for otc products the boosts gross margins percentage points versus pharmacy channels. end-2025 hosts personalized health subscriptions-over active subscribers-and exclusive online-only bundles representing of dtc sales. channel reduces customer acquisition cost about per user raises repeat purchase rate\u003e\n\u003c\/pildong\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Clinic Sales Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals deploys ~1,200 medical representatives (2025) to manage B2B ties with major hospitals and ~25,000 local clinics, securing placement for cardiovascular and gastrointestinal drugs in formularies.\u003c\/p\u003e\n\u003cp\u003eThis channel generated an estimated ₩280 billion (KRW) in prescription sales in 2024, roughly 62% of its domestic Rx revenue, driving steady prescription volumes.\u003c\/p\u003e\n\u003cp\u003eFocused detailing and hospital trials boost brand loyalty among clinicians, translating to repeat prescriptions and longer product life cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Export and Partnership Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpildong pharmaceuticals has grown exports of apis and finished drugs to southeast asia the middle east south america accounting for about revenue krw firm uses local distributors strategic alliances clear regulatory hurdles secure market access cutting domestic-market reliance from in\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExports to 3 regions: 18% revenue (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue 2024: KRW 1.22trn; export KRW 220bn\u003c\/li\u003e\n\u003cli\u003eDomestic share fell from 85% (2019) to 72% (2024)\u003c\/li\u003e\n\u003cli\u003eLocal distributors and alliances drive regulatory entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pildong\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party Logistics and Cold Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIldong Pharmaceuticals has invested in advanced cold chain systems-including refrigerated warehouses and temperature-monitoring IoT-cutting cold-chain breaches by an estimated 35% and preserving potency of biologics and probiotics during transit.\u003c\/p\u003e\n\u003cp\u003eThese logistics upgrades support same-week restocking across 1,200+ retail and medical locations in South Korea, reducing stock-outs by about 22% and improving on-shelf availability for critical products.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% fewer cold-chain breaches\u003c\/li\u003e\n\u003cli\u003e1,200+ retail\/medical endpoints\u003c\/li\u003e\n\u003cli\u003e~22% reduction in stock-outs\u003c\/li\u003e\n\u003cli\u003eSame-week restocking capability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong: 12k+ pharmacies, KRW45bn DTC, 18% exports, cuts breaches 35%-same-week restock\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong's place strategy combines 12,000+ pharmacy reach, 1,200+ retail\/medical endpoints with same-week restock, 1,200 MRs (2025) for 25,000 clinics\/hospitals, Ildong Mall DTC GMV KRW45bn (2024) with 60k subs, exports 18% of revenue (KRW220bn, 2024), and cold-chain cuts breaches 35%, reducing stock-outs ~22%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (date)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003e12,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\/medical endpoints\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIldong Mall GMV\u003c\/td\u003e\n\u003ctd\u003eKRW45bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscribers\u003c\/td\u003e\n\u003ctd\u003e60,000 (end-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExports\u003c\/td\u003e\n\u003ctd\u003eKRW220bn \/18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain breaches\u003c\/td\u003e\n\u003ctd\u003e-35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock-outs\u003c\/td\u003e\n\u003ctd\u003e-22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eIldong Pharmaceuticals 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Ildong Pharmaceuticals 4P's Marketing Mix Analysis you'll receive instantly after purchase-no surprises. It's the identical, fully complete document available for immediate download, editable and ready to use for strategic planning or presentations. Buy with confidence knowing this is the final, high-quality analysis included in your order.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eromotion\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeritage Based Mass Media Advertising\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals keeps top-of-mind awareness for legacy brands via high-impact TV and print ads, driving a reported 12% annual brand recall uplift for Aronamin in 2024 and supporting 8% revenue growth in its consumer healthcare segment that year.\u003c\/p\u003e\n\u003cp\u003eCampaigns highlight Aronamin's 70+ year history and reliability, using emotional storytelling to connect across generations and raise purchase intent by 6-9% in target demographics according to 2024 post-campaign surveys.\u003c\/p\u003e\n\u003cp\u003eBy end of 2025 these traditional ads are tightly integrated with modern visual branding-consistent logos, color systems, and short-form clips-helping reduce ad creative fatigue and sustaining a 15% higher engagement on digital channels versus 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Marketing and Social Media Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals uses targeted social ads, influencer partnerships, and YouTube educational videos to boost MyNi and Biovita among young parents and health-conscious millennials.\u003c\/p\u003e\n\u003cp\u003eIn 2025 the company reported a 28% YoY rise in digital-sourced sales and a 42% increase in engagement for MyNi campaigns, driven by micro-influencers averaging 3-5% engagement rates.\u003c\/p\u003e\n\u003cp\u003eData-driven segmentation lets Ildong deliver tailored messages based on health interests and browsing behavior, raising conversion rates by an estimated 1.8x versus broad campaigns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Symposia and Medical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePromotion in Ildong Pharmaceuticals' prescription division centers on scientific credibility via academic seminars and webinars for clinicians, showcasing clinical trial data-eg, 2024 phase III results reporting a 22% relative risk reduction in major adverse cardiovascular events for its lead CV drug-and therapeutic benefits of metabolic treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate Social Responsibility Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIldong Pharmaceuticals boosts brand reputation via CSR programs-drug donations and health-education workshops in underserved areas-showing public-welfare commitment beyond profit; by 2024 Ildong reported over 12,000 donated medicine units and 150 community workshops, strengthening stakeholder trust.\u003c\/p\u003e\n\u003cp\u003eThese promotions build long-term brand equity and a positive corporate identity, supporting patient loyalty and partner goodwill while aligning with global healthcare ESG trends.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12,000+ medicine units donated (2024)\u003c\/li\u003e\n\u003cli\u003e150 community workshops (2024)\u003c\/li\u003e\n\u003cli\u003eImproved stakeholder trust and brand equity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-Store Merchandising and Pharmacist Incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIldong places branded display units and 10,000+ educational brochures in Korean pharmacies, lifting shelf visibility by an estimated 18% and in-store trial by 12% in 2024.\u003c\/p\u003e\n\u003cp\u003ePharmacist training programs reached 4,200 pharmacists in 2024, improving recommendation rates for Ildong OTCs by ~22% during face-to-face consultations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e10,000+ brochures deployed in 2024\u003c\/li\u003e\n\u003cli\u003e18% higher shelf visibility\u003c\/li\u003e\n\u003cli\u003e12% increase in trial\u003c\/li\u003e\n\u003cli\u003e4,200 pharmacists trained\u003c\/li\u003e\n\u003cli\u003e22% boost in recommendations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong's omni-channel push boosts recall, sales, engagement and HCP trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong's promotion blends legacy TV\/print (Aronamin: 12% recall uplift, 8% CHC revenue growth 2024) with digital (MyNi: 28% digital sales rise 2025; 42% engagement lift) and HCP-focused scientific outreach (2024 CV Phase III: 22% RRR); CSR and pharmacy programs (12,000+ donated units, 150 workshops, 10,000+ brochures, 4,200 pharmacists trained) drive trust and in-store trial gains.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey 2024-25 metrics\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTV\/Print (Aronamin)\u003c\/td\u003e\n\u003ctd\u003e12% recall ↑; 8% CHC sales ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital (MyNi\/Biovita)\u003c\/td\u003e\n\u003ctd\u003e28% digital sales ↑; 42% engagement ↑\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical outreach\u003c\/td\u003e\n\u003ctd\u003ePhase III: 22% RRR (CV drug)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCSR \u0026amp; Pharmacy\u003c\/td\u003e\n\u003ctd\u003e12,000+ units; 150 workshops; 10,000+ brochures; 4,200 pharmacists\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erice\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Health Insurance Reimbursement Pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA significant share of Ildong Pharmaceuticals' prescription revenue is set by South Korea's National Health Insurance Service (NHIS); in 2024 NHIS reimbursements covered roughly 67% of domestic drug sales for comparable mid-sized firms. Ildong must negotiate reimbursement ceilings that cap margins, and price cuts follow regulatory reforms and generic entry-Korean generics cut originator prices by ~30% on average within 12-18 months of launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium Pricing Strategy for Legacy Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor legacy brands like Aronamin, Ildong keeps premium pricing to signal quality and leverage brand equity; Aronamin sold at ~25-40% price premium over generics in South Korea in 2024, per Euromonitor data. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetitive Generic Pricing Structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong Pharmaceuticals uses competitive generic pricing to capture share from originators and rivals, targeting 5-10% price undercuts versus incumbents to win volume; in 2024 this helped grow its generics revenue by 12% to KRW 210 billion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Pricing for New Innovations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs Ildong shifts to value-based pricing for proprietary drugs, prices tie to measured clinical gains-mortality reduction, quality-adjusted life years (QALYs), or hospital-day cuts-to reflect true patient value.\u003c\/p\u003e\n\u003cp\u003eJustification rests on better outcomes and lower lifetime costs; global value-based deals reached 15-20% of pharma launches by 2024, supporting premium pricing that recoups high R\u0026amp;D spend.\u003c\/p\u003e\n\u003cp\u003eRecovering R\u0026amp;D: average cost per novel drug around $2.1bn (2020-2022 studies), so Ildong prices must balance access and return to fund pipeline growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTie price to QALY gains and real-world outcomes\u003c\/li\u003e\n\u003cli\u003eTarget value deals with payers to enable uptake\u003c\/li\u003e\n\u003cli\u003eSet premiums reflecting ~$2.1bn average R\u0026amp;D per novel drug\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTiered Pricing for Consumer Health Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIldong uses tiered pricing for health functional foods and probiotics to reach multiple income groups; entry-tier items start around KRW 9,900 (≈USD 7.5) while premium probiotic lines sell at KRW 49,000-99,000 (≈USD 37-75) per pack as of 2025.\u003c\/p\u003e\n\u003cp\u003eThis mix lets Ildong capture mass-market volume and high-margin premium buyers; in 2024 its consumer health division grew ~12% YoY, driven by premium SKUs contributing ~28% of category revenue.\u003c\/p\u003e\n\u003cp\u003eHere's the quick math: wider price bands raise total addressable market and average selling price, boosting revenue without abandoning value shoppers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEntry price ~KRW 9,900\u003c\/li\u003e\n\u003cli\u003ePremium price KRW 49k-99k\u003c\/li\u003e\n\u003cli\u003e2024 growth ~12% YoY\u003c\/li\u003e\n\u003cli\u003ePremium share ~28% of revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIldong boosts ASP with tiered pricing while NHIS limits and fast generic cuts bite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIldong's pricing is constrained by NHIS reimbursements (~67% of domestic sales, 2024) and rapid generic-driven cuts (~30% within 12-18 months). It keeps 25-40% premiums on legacy Aronamin, undercuts incumbents 5-10% for generics (2024 generics revenue KRW 210bn, +12% YoY), and uses tiered consumer prices KRW 9,900-99,000 to lift ASP and reach segments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNHIS share\u003c\/td\u003e\n\u003ctd\u003e~67%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric price cut\u003c\/td\u003e\n\u003ctd\u003e~30% (12-18m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAronamin premium\u003c\/td\u003e\n\u003ctd\u003e25-40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics rev\u003c\/td\u003e\n\u003ctd\u003eKRW 210bn (+12%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer price band\u003c\/td\u003e\n\u003ctd\u003eKRW 9,900-99,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTLE Analysis","offers":[{"title":"Default Title","offer_id":52824278106378,"sku":"ildong-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0944\/6414\/7722\/files\/ildong-marketing-mix.webp?v=1775686509","url":"https:\/\/pestle-analysis.com\/products\/ildong-marketing-mix","provider":"PESTLE Analysis","version":"1.0","type":"link"}